Kanabo Group appoints Gil Efron as a Non-Executive Director
(KNB ) has announced the appointment of Gil Efron as a Non-Executive Director and the retirement of Uzi Danino, the current Chairman of its Audit Committee.
The Israeli-based medicinal cannabis group’s audit committee is currently chaired by Danino who will retire as a Non-Executive Director immediately to focus on other business interests. Following the retirement of Danino, Efron will take over as Chairman of the Audit Committee.
Efron is serving as President and Chief Financial Officer of NASDAQ and TASE dual-listed Purple Biotech Ltd., a clinical-stage company (PPBT) since June 2021, having previously held the position of Deputy Chief Executive Officer and Chief Financial Officer from October 2018.
Prior to his current tenure at Purple Biotech, he served as Deputy CEO and CFO of Kamada, a NASDAQ and TASE dual-listed plasma-derived protein therapeutics firm during 2011-2017.
Avihu Tamir, Founder and CEO of Kanabo Group, said: “We are delighted to welcome Gil to the board. His wealth of experience in the capital market will be an excellent addition to Kanabo’s Board, as well as his vast business and financial management experience.”
Tamir added: “The Board and I would like to thank Uzi for his tireless dedication in bringing Kanabo to the listed market in the UK. We have benefited greatly from his experience and counsel over the past 3.5 years and wish him well in all his future endeavours.”
Last month, Kanabo Group announced that it had acquired The GP Service, a private primary care telemedicine provider, in an all-share deal for a total consideration of £13.5 million at a price of 12.65p which represents around 22% of the issued share capital of the Company.
The Israeli-based medicinal cannabis firm said it expects the acquisition to facilitate the ‘rapid growth’ of its existing digital and telemedicine business while also establishing ‘a new and fully compliant channel’ to market for the business’ products for medical patients, it explained.
‘Through improved access to these products, Kanabo Group hopes to make a substantial contribution to improving outcomes for thousands of patients in the UK and Europe,’ it said.
Kanabo intends to develop a platform to become one of Europe’s first digitally led and legally compliant providers for its products and wellness CBD services following regulatory approval.
Follow News & Updates from :
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.